Quantum-Si (QSI) investor relations material

Strategic direction and product development

• Focus over the next 12–18 months is on completing Proteus platform development and ensuring a successful commercial launch in Q2 2027, with Platinum serving as a market development tool to onboard users and generate evidence.

• Additional upside is expected from potential partnerships and collaborations leveraging the platform.

• The decision to delay Proteus launch to Q2 2027 was internally driven to improve repeatability and manufacturing consistency, not due to technology or customer issues.

• An extra design cycle was added to de-risk production, focusing on refining specifications, end-of-line testing, and improving both pre-instrument and instrument workflows.

• Organizational structure was flattened, with all key R&D disciplines reporting directly to the CEO, and increased support from development partners to ensure product readiness.

Technology and market positioning

• Single molecule protein sequencing enables direct, reference-free sequencing of proteins, offering complete sequence information and detection of post-translational modifications, surpassing traditional mass spectrometry and immunoassays.

• Recent advancements allow detection of 18 amino acids, with a goal to reach 20 by launch, unlocking broader applications and aligning with customer expectations.

• AI-driven tools trained on proprietary data have accelerated the identification and optimization of protein recognizers, improving sequencing capabilities.

• Road shows in the U.S. and Europe are used to educate potential customers, gather feedback, and identify early adopters, with European markets showing more interest in multi-omic approaches.

• Early adoption is expected primarily from academic institutions, with pharma and defense sectors also showing interest, especially for biothreat applications.

Commercial readiness and milestones

• Workforce reduction extended cash runway into Q4 2028, ensuring sufficient resources for launch and initial commercial ramp.

• Commercial team is focused on maintaining customer engagement through road shows and sample data generation, with plans to scale further based on uptake post-launch.

• Key milestones to watch include progress on amino acid coverage, instrument integration cycles, placement with external users, and potential pre-orders.